Free Trial
ASX:CUV

Clinuvel Pharmaceuticals (CUV) Stock Price, News & Analysis

Clinuvel Pharmaceuticals logo

About Clinuvel Pharmaceuticals Stock (ASX:CUV)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
124,193 shs
Average Volume
N/A
Market Capitalization
$563.18 million
P/E Ratio
15.95
Dividend Yield
0.44%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Remove Ads
Receive CUV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clinuvel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CUV Stock News Headlines

High Growth Tech Stocks In Australia For March 2025
New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
Clinuvel Pursues Expanded SCENESSE® Dosage in Europe
See More Headlines

CUV Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Clinuvel Pharmaceuticals investors own include Cochlear (COH), CSL (CSL), ResMed (RMD), ARB (ARB), Accent Group (AX1), Corporate Travel Management (CTD) and Mineral Resources (MIN).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:CUV
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
15.95
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$35.64 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$88.18 million
Price / Cash Flow
19.36
Book Value
A$4.02 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$563.18 million
Optionable
Not Optionable
Beta
0.92
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (ASX:CUV) was last updated on 4/6/2025 by MarketBeat.com Staff
From Our Partners